English
Español
Português
Home
About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Committees of Board
Management Team
Corporate Governance Report
Mission, Vision and Values
Environment
Products
Research & Development
Product Development
R & D Capabilities
Infrastructure
Capacities and Capabilities
Regulatory Approvals
Environmental/Social Information
Investor Relations
Overview
Corporate Details
Company Finanicals
Shareholders feedback form
Code of Conduct
News and Media
Careers
Contact Us
Sales Offices
Enquiry Form
FAQs
Investor Relations
Overview
Corporate Details
Company Financials
Annual Reports
Quarterly Reports
Shareholding Pattern
Shareholders feedback form
Code of Conduct
News and Media
Granules in Media
Press Releases
Contact
Granules Investor Enquiry
Ms. Shivangi Sharma
Company Secretary &
Compliance Officer
Tel: +91-40-6676-0000
Fax: +91-40-2311-5145
E-mail:
shivangi.sharma@granulesindia.com
investorrelations@granulesindia.com
Press Releases
2012
Granules India’s revenue increases to Rs. 176 Cr.; net profit increased by 228%
Granules India Awarded Outstanding Exports – Formulations Award 2011-12 by Pharmexcil
Granules India Awarded India’s Most Admired Company in Exports & India’s Most Admired Company in Bulk Drugs
Granules India’s Sales increases 59% to Rs. 189 Cr.; Net Profit up 100%
Granules India Announces Dividend Increase of 33%; second consecutive increase
Granules India Announces New Chief Financial Officer
Granules India’s FY12 Revenue increases 37% to Rs. 653 Cr.; Net Profit increases 43% to Rs. 30 Cr
Granules India’s Sales increase 45% to Rs. 186 Cr.; Net Profit up 42%
2011
Granules India’s Net Revenue soars 37%; PBT before non-cash expense jumps 70%
Granules India Receives U.S. FDA Approval for its Naproxen Sodium ANDA
Granules India’s Net Revenue increases 9% due to strong formulation sales
Granules India and Ajinomoto OmniChem to create a strategic Joint Venture in India
Granules India’s Net Profit excluding exceptional items increases 21%; Dividend to be increased by 20%
2010
Granules India Announces New Leadership Roles.
Granules India Posts Revenue of Rs.109.3 Cr. for Q1 FY11.
Granules India Posts Strong Growth During FY’10: Net Revenue of Rs. 461.1 Cr.
Granules India Receives U.S. FDA Approval for its Metformin ANDA
Granules India Posts Record Revenue for a Quarter: Net Revenue of Rs. 122.40 Cr. Posted for Q3 FY’10
2009
Granules Posts Record Revenue, Net Profit Increases 121%
2008
Granules India Q2 FY08 Net sales up 5.44 per cent at Rs 53 crore
2007
Granules India Limited Posts an increase of 37% in TURNOVER and 35% on NET PROFITS
Granules India FY07 Net Profit up 14.61 per cent at Rs 10.59 crs.
Granules India invites shareholders approval for IFC investment.
Granules India Ltd., is pleased to announce the approval of its facilities in the recently conducted audit by US FDA.
HERITAGE and GRANULES enter Into Strategic Alliance for the Development, Supply and Marketing.
2006
PharmaMatch B.V., and Granules India Limited are pleased to announce the signing of a Memorandum of Understanding.
Granules India achieves higher EBITDA.